Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

July 5, 2022, 9:54 a.m. EDT

Novavax stock rallies after EU expands CMA on COVID vaccine for 12 to 17-year olds

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Novavax Inc. /zigman2/quotes/202614340/composite NVAX -3.89% surged 4.4% toward a two-month high in morning trading Tuesday, to buck the selloff in the broader stock market, after the biotechnology company said its COVID-19 vaccine Nuvaxovid received expanded conditional marketing authorization (CMA) from the European Commission (EC) for people aged 12 through 17. Novavax's COVID vaccine has not yet been authorized for use in the U.S., and the trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration. The company said the EU authorization was based on data showing the vaccine was well tolerated, and shoed 80% clinical efficacy at a time that the delta variant was dominant. "With this authorization, we are extremely pleased to be able to offer our Nuvaxovid COVID-19 vaccine to adolescents in the EU," said Chief Executive Stanley Erck. The stock has tumbled 58.3% year to date, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB +0.27% has slid 21.6% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.27% has dropped 21.2%.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 57.93
-2.35 -3.89%
Volume: 3.97M
Aug. 8, 2022 2:48p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.71 billion
Rev. per Employee
$910,469
loading...
/zigman2/quotes/206189322/composite
US : U.S.: Nasdaq
$ 131.79
+0.35 +0.27%
Volume: 2.19M
Aug. 8, 2022 2:48p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,134.02
-11.17 -0.27%
Volume: 2.22B
Aug. 8, 2022 2:48p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.